Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here for more information

Sign In to gain access to subscriptions and/or personal tools.
Journal of Biomolecular Screening
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
1087057108323127v1
13/9/855    most recent
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hostetler, H. A.
Right arrow Articles by Kier, A. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hostetler, H. A.
Right arrow Articles by Kier, A. B.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

A Novel High-Throughput Screening Assay for Putative Antidiabetic Agents through PPAR{alpha} Interactions

Heather A. Hostetler

Department of Physiology and Pharmacology, Texas A&M University, TVMC, College Station, Texas

Lindsay R. Syler

Department of Pathobiology, Texas A&M University, TVMC, College Station, Texas

Lindy N. Hall

Department of Physiology and Pharmacology, Texas A&M University, TVMC, College Station, Texas

Guan Zhu

Department of Pathobiology, Texas A&M University, TVMC, College Station, Texas

Friedhelm Schroeder

Department of Physiology and Pharmacology, Texas A&M University, TVMC, College Station, Texas

Ann B. Kier

Department of Pathobiology, Texas A&M University, TVMC, College Station, Texas, akier{at}cvm.tamu.edu

As natural peroxisome proliferator-activated receptor-{alpha} (PPAR{alpha}) ligands, high levels of fatty acids and glucose could lead to hyperactivation of PPAR{alpha}, like that seen in diabetes. Important diabetes research goals are to uncover new metabolic or signaling pathways involved in hyperglycemic cellular injury and to develop therapeutics for preventing or reversing this injury. Consequently, 1040 putative antidiabetic agents were screened for their ability to 1) affect PPAR{alpha} lipid binding, 2) directly bind PPAR{alpha}, and 3) alter PPAR{alpha} transactivation in the presence of high glucose. A high-throughput fluorescent binding assay was developed to examine each compound's ability to restore fatty acyl-CoA binding to PPAR{alpha} in the presence of high glucose concentrations. Approximately 1% of the compounds restored acyl-CoA binding by 60% or more. These compounds directly interacted with PPAR{alpha} with high affinity (nM Kds), validating the primary screen. Furthermore, these compounds altered PPAR{alpha} transactivation, and 1 strongly reversed the hyperactivation of PPAR{alpha} found in the presence of clofibrate and high glucose levels. (Journal of Biomolecular Screening 2008:855-861)

Key Words: nuclear transcription factors • peroxisome proliferator-activated receptors • fluorescent binding assays • glucose

This version was published on October 1, 2008

Journal of Biomolecular Screening, Vol. 13, No. 9, 855-861 (2008)
DOI: 10.1177/1087057108323127


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?